Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer

Urology

Volumn 49, Issue 5, 1997, Pages 668-672

  Critz, Frank A ^a,b   Levinson, Keith ^a   Williams, W Hamilton ^a   Holladay, David ^a   Holladay, Clinton ^a   Griffin, Vivian ^a  

^a Radiotherapy Clinics of Georgia   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

EID: 0030903487     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00084-8     Document Type: Article

References (20)

1. Schellhammer PF, El-Mahdi AM, et al: Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology 42: 13-20, 1993.
2. Zelefsky MJ, Leibel SA, et al: Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostate cancer. J Clin Urol 133: 459-463, 1995.
3. Powell CR, Huisman TK, et al: Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy (abstract). J Urol 155(suppl): 560A, 1996.
4. Hanks GE, Perez CA, et al: PSA confirmation of cure at 10 years of TIB, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys 30: 289-292, 1994.
5. Gottesman JE, Tesh DG, et al: Failure of open radioactive 125 iodine implantation to control localized prostate cancer: a study of 41 patients. J Urol 146: 1317-1320, 1991.
6. Stock RG, Stone NN, et al: Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 77: 2386-2392, 1996.
7. Goad JR, Chang S, Ohori M, and Scardino PT: PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am 20: 727-736, 1993.
8. Critz FA, Tarlton RS, and Holladay DA: Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. Cancer 75: 2383-2391, 1995.
9. Critz FA, Levinson AK, Williams WH, and Holladay DA: Is an undetectable nadir PSA a reasonable goal following irradiation for prostate cancer (abstract)? J Urol 155(suppl): 557A, 1996.
10. Critz FA, Levinson AK, Williams WH, and Holladay DA: Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. J Clin Oncol 14: 2893-2900, 1996.
11. Critz FA, Levinson AK, Williams WH, Holladay DA, and Holladay CT: The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology (in press).
12. Stamey TA, Yemoto C, and McNeal JE: A histological analysis of probable causes of biochemical failure after radical prostatectomy for clinical stages T1c-T2 cancers (abstract). J Urol 155(suppl): 487A, 1996.
13. Partin AW, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Serum PSA after anatomic radical prostatectomy. Urol Clin North Am 20: 713-725, 1993.
14. Trapasso JG, deKernion JB, Smith RB, and Dorrey F: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152: 1821-1825, 1994.
15. Frazier HA, Robertson JE, Humphrey PA, and Paulson DF: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 149: 516-518, 1993.
16. Gehan EA: Estimating survival functions from the life table. J Chronic Dis 21: 629-644, 1969.
17. Cox D: Regression models and life tables. J R Stat Soc B 34: 187-220, 1972.
18. Whitmore WF, Hilaris B, and Grabstald H: Retropubic implantation of iodine 125 in the treatment of prostate cancer. J Urol 108: 918-920, 1972.
19. Lee WR, Hanlon AL, and Hanks GE: Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease free survival. J Urol 156: 450-453, 1996.
20. Zietman AL, Coen JJ, Shipley WU, Willett CG, and Efird JT: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151: 640-645, 1994.